European Markets for Prosthetic Vascular Grafts

Many large and growing diseases, such as diabetes, cause vessel damage calling for replacement vascular grafts. The European market for prosthetic vascular grafts is today a $343 million industry and growing, according to "The European Prosthetic Vascular Grafts Market," a report just issued y Medtech Insight.

Grafts and corruption. This is a problem in Europe, as in the rest of the world, medically speaking that is. Many prevalent diseases cause vessel damage that necessitates replacement vascular grafts, and a large number of manufacturers–CR Bard Inc. , Boston Scientific Corp. , B. Braun Melsungen AG , Cook Group Inc. , Cordis Corp. , WL Gore & Associates Inc. , DataScope Corp. , Medtronic Inc. and Terumo Corp. —have taken up the challenge of trying to meet the standards of Mother Nature in replacing damaged vessel segments. It’s tough to do, but the attempt has created a $343 million industry in Europe, and it’s growing, according to "The European Prosthetic Vascular Grafts Market," a report just issued by the Medtech Insight division of Windhover Information Inc.

In Europe, the number of patients receiving prosthetic vascular grafts is expected to increase due to the aging of the...

Welcome to Medtech Insight

Create an account to read this article

More from Europe

FDA Changes Fail To Diminish US Appeal To European Medtech Industry

 

Despite staffing cuts and uncertainty at the FDA, the US still offers EU medtech firms stronger regulatory support, regulatory expert Bassil Akra told Medtech Insight. This is especially valued as EU rules are often viewed as overly stringent, unclear and difficult to follow.

Cardiology And PTA Procedures In Germany’s Expanded Hybrid DRGs List 2026

 
• By 

2026 reimbursement calculations for the list of hybrid DRGs – a mechanism to incentivize day cases over inpatient surgery – will be issued in few weeks’ time. The medtech industry has made its demands known.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

EU4Health Boost For Orphan Devices And SMEs

 
• By 

EU4Health, the main funding instrument for EU health initiatives, has put renewed emphasis on orphan devices in its 2025 work program, published in July.

More from Geography

Cardiology And PTA Procedures In Germany’s Expanded Hybrid DRGs List 2026

 
• By 

2026 reimbursement calculations for the list of hybrid DRGs – a mechanism to incentivize day cases over inpatient surgery – will be issued in few weeks’ time. The medtech industry has made its demands known.

Biden-Era Device Trial Snapshot Pilot Halted Amid DEI Policy Shift

 
• By 

The FDA's Device Clinical Trial Snapshot Pilot, aimed at increasing trial transparency and diversity, has been canceled following President Trump’s anti-DEI executive order. Critics warn this may hinder trial transparency, impacting public health and demographic data accessibility.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.